The cost-effectiveness of automatic implantable cardiac defibrillators: Results from MADIT

Circulation

Volumn 97, Issue 21, 1998, Pages 2129-2135

  Mushlin, Alvin I ^a,b   Hall, W Jackson ^a   Zwanziger, Jack ^a   Gajary, Elizabeth ^a   Andrews, Mark ^a   Marron, Rebecca ^a   Zou, Kelly H ^a   Moss, Arthur J ^a  

^a UNIVERSITY OF ROCHESTER   (United States)

^b UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

Author keywords

Cardioversion; Cost effectiveness; Defibrillation

Indexed keywords

ARTICLE; AUTOMATIC CARDIOVERSION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DEFIBRILLATION; DEFIBRILLATOR; HEALTH CARE COST; HEART VENTRICLE TACHYCARDIA; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

EID: 0032474426     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.97.21.2129     Document Type: Article

References (25)

1. Gillum RF. Sudden coronary death in the United States: 1980-1985. Circulation. 1989;79:736-765.
2. Ruskin JN, McGovern B, Garan H, Dimarco JP, Kelly E. Antiarrhythmic drugs: a possible cause of out-of hospital cardiac arrest. N Engl J Med. 1983;309:1302-1306.
3. Echt DS, Liebson PR, Mitchell LB, Peters RW,Objas-Manno D, Barker AH, Arensberg D, Baker A, Friedman L, Greene HL, Huther ML, Richardson DW, the CAST Investigators. Mortality and morbidity in patients receiving encainide, flecainide, or placebo: the Cardiac Arrhythmia Suppression Trial. N Engl J Med. 1991;324:781-788.
4. Mason JW. A comparison of seven antiarrhythmic drugs in patients with ventricular tachyarrhythmias. N Engl J Med. 1993;329:452-458.
5. Moss AJ, Hall WJ, Cannom DS, Dauben JP, Higgins SL, Levine JH, Saksena S, Waldo AL, Wilber D, Brown MW, Heo M. Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. N Engl J Med. 1996;335:1933-1940.
6. MADIT Executive Committee. Multicenter Automatic Defibrillator Implantation Trial (MADIT): design and clinical protocol. Pacing Clin Electrophysiol. 1991;14:920-927.
7. Mushlin AI, Zwanziger J, Gajary E, Andrews M, Marron R. Approach to cost-effectiveness assessment in the MADIT trial. Am J Cardiol. 1997; 80:33F-41F.
8. Mitchell JB, Surge RT, Lee AJ, McCall NT, Katz LW, Dittus R, Heck D, Kinney EA, Parchman M, Iezzoni L. Per Case Prospective Payment for Episodes of Hospital Care. Waltham, Mass: Health Economics Research, Inc; 1995. Final report prepared for the Health Care Financing Administration under contract No. 500-92-0020.
9. Health Care Financing Administration Common Procedure Coding System, National Level II Medicare Codes. Los Angeles, Calif: Practice Management Information Corp; 1995.
10. Drug Topics Red Book. Montvale, NJ: Medical Economics Company, Inc; 1995.
11. Gardiner J, Hogan A, Holmes-Rovner M, Rovner D, Griffith L, Kuppersmith J. Confidence intervals for cost-effectiveness ratios. Med Decis Making. 1995;15:254-263.
12. Efron E, Tibshirani RJ, An Introduction to the Bootstrap. New York, NY: Chapman & Halll; 1993;170-171.
13. Hlatky MA, Rogers WJ, Johnstone I, Boothroyd D, Brooks MM, Pitt B, Reeder G, Ryan T, Smith H, Whitlow P, Wiens R, Mark DB. Medical care costs and quality of life after randomization to coronary angioplasty or coronary bypass surgery. N Engl J Med. 1997;336:92-99.
14. Cox DR, Oakes DO. Analysis of Survival Data. London, UK: Chapman & Hall; 1984:41-43.
15. Owens DK, Sanders CD, Harris RA, McDonald KM. Cost-effectiveness of implantable cardioverter defibrillators relative to amiodarone for prevention of sudden cardiac death. Ann Intern Med. 1997;126:1-12.
16. Drummond MF. Economic evaluation and the rational diffusion and use of health technology. Health Policy. 1987;7:309-324.
17. Kupperman M, Luce BR, McGovern B, Podrid PJ, Bigger T Jr, Ruskin TN. An analysis of the cost-effectiveness of the implantable defibrillator. Circulation. 1990;81:91-100.
18. Larsen GC, Manolis AS, Sonnenberg FA, Beshanksky JR, Estes NAM, Pauker SG. Cost-effectiveness of the implantable cardioverterdefibrillator: effect of improved battery life and comparison with amiodarone therapy. J Am Coll Cardiol. 1992;19:1323-1324.
19. Kuppersmith J, Hogan A, Guerrero P, Gardiner J, Mellitis ED, Baumgarder R, Rovner D, Holmes-Rovner M, McLane A, Levine J, Saksena S, Griffith L. Evaluating and improving the cost-effectiveness of the implantable cardioverter-defibrillator. Am Heart J. 1995;130: 507-515.
20. Wever EFD, Hauer RNW, Schrijvers G, van Capelle FJL, Tijssen JGP, Crijns HJGM, Algra A, Ramanna H, Bakker PFA, de Medina EOR. Cost-effectiveness of implantable defibrillator as first-choice therapy versus electrophysiologically guided, tiered strategy in postinfarct sudden death survivors: a randomized study. Circulation. 1996;93:489-496.
21. O'Donoghue S, Platia EV, Brooks-Robinson S, Mispireta L. Automatic implantable cardioverter-defibrillator: is early implantation costeffective? J Am Coll Cardiol. 1990;16:1258-1263.
22. Anderson MH, Camm AJ. Implications for present and future applications of the implantable cardioverter-defibrillator resulting from the use of a simple model of cost efficacy. Br Heart J. 1993;69:83-92.
23. O'Brien BJ, Buxton MJ, Rushby JA. Cost effectiveness of the implantable cardioverter defibrillator: a preliminary analysis. Br Heart J. 1992;68:241-245.
24. Siegel JE, Weinstein MC, Torrance GW. Reporting cost-effectiveness studies and results. In: Gold MR, Siegel JE, Russell LB, Weinstein MC, eds. Cost Effectiveness of Health and Medicine. New York, NY: Oxford University Press; 1996:276-303.
25. Friedman PL, Stevenson WG. Unsustained ventricular tachycardia: to treat or not to treat. N Engl J Med. 1996;335:1984-1985.